Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

ONMD - OneMedNet Corporation Последние новости | Finranks

Home

ONMD

O

OneMedNet Corporation (ONMD)

NCM – Цена в реальном времени. Валюта: USD

0.89

+0.01 (1.09%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

0.87

-0.02 (-1.96%)

После закрытия: Mar 27, 2026, 7:50 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence. What This Collaboration Means for the Pharma Market Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training.

What's Going On With Penny Stock OneMedNet On Tuesday?

What's Going On With Penny Stock OneMedNet On Tuesday?

OneMedNet (NASDAQ: ONMD) shares are trading lower on Tuesday, possibly on continued weakness after the stock rallied on Friday following a recent announcement about the next phase of its real-world data (RWD) platform.

OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions.

OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a digital health company specializing in autoimmune disease populations. This partnership expands OneMedNet's autoimmune clinical ontology, to the OneMedNet iRWD™ platform—powered by Palantir Foundry—further increasing the scale, diversity, and longitudinal depth of its regulatory-grade Real-World Data.

OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers

OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers

MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms for central nervous system (CNS) indications across neurology, psychiatry, and sleep.

OneMedNet Reports Record 2025 Bookings of $2.79 Million, Surpassing Prior Year by More Than 4.1X and Accelerating Subscription Transition

OneMedNet Reports Record 2025 Bookings of $2.79 Million, Surpassing Prior Year by More Than 4.1X and Accelerating Subscription Transition

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), today announced record bookings in 2025 of data-delivery agreements totaling $2.79 million of contract value, exceeding 2024 bookings by more than four times (4X). The milestone reflects increasing deal size, strong enterprise demand, and meaningful progress toward a recurring subscription model.

OneMedNet Real-World Data Supports FDA 510(k) Clearance of AI-Powered Scaida BrainCT-ICH Software

OneMedNet Real-World Data Supports FDA 510(k) Clearance of AI-Powered Scaida BrainCT-ICH Software

MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced that its high-quality, multimodal clinical data supported mlHealth 360 in obtaining U.S. Food and Drug Administration (FDA) 510(k) clearance for Scaida BrainCT-ICH, an AI-powered software solution designed to facilitate the rapid detection of intracranial hemorrhage (ICH) from head computed tomography (CT) scans. Scaida BrainCT-ICH leverages artificial intelligence to analyze head CT images and identify suspected intracranial hemorrhage in approximately 5.97 seconds after image acquisition, enabling faster clinical triage and supporting timely decision-making in acute care settings, according to mlHealth 360.

Видео

No Data

There is no data to display

Пресс-релизы

OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence. What This Collaboration Means for the Pharma Market Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training.

OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions.

OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a digital health company specializing in autoimmune disease populations. This partnership expands OneMedNet's autoimmune clinical ontology, to the OneMedNet iRWD™ platform—powered by Palantir Foundry—further increasing the scale, diversity, and longitudinal depth of its regulatory-grade Real-World Data.

OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers

OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers

MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms for central nervous system (CNS) indications across neurology, psychiatry, and sleep.